Summary by Moomoo AI
Cingulate Inc., a biopharmaceutical company based in Delaware, filed a post-effective amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on April 1, 2024. This amendment pertains to the registration of 5,973,000 shares of common stock underlying warrants previously issued in connection with Cingulate's public offering that closed on February 6, 2024. The shares are issuable upon the exercise of pre-funded, Series A, Series B, and placement agent warrants, with exercise prices ranging from $0.0001 to $2.50 per share. The amendment updates financial and other information from the original registration statement, which was declared effective by the SEC on February 2, 2024. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. Cingulate's common stock is listed on the Nasdaq Capital Market under the symbol 'CING', with the last reported sale price on March 28, 2024, being $1.10 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.